SENS vs UNH

Senseonics (SENS) continues to present an extremely high-risk, high-reward profile with the path to 10x potential remaining significantly challenging. While the Eversense long-term implantable CGM offers a unique proposition in the vast diabetes market, previous commercialization struggles and persistent cash burn are still critical concerns. The market cap has slightly adjusted from the previous ...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...